In the 2025 American Heart Association/American College of Cardiology hypertension guideline, management of hypertension in adults ≥65 years has shifted from an age-based to a risk-based approach. Unlike prior guidance, age alone no longer mandates pharmacologic therapy for stage 1 hypertension (130–139/80–89 mm Hg). Instead, treatment is recommended if the patient has ≥7.5% 10-year cardiovascular risk (PREVENT) or established CVD, diabetes, or CKD; otherwise, lifestyle therapy is initiated with reassessment in 3–6 months. Patients with BP ≥140/90 mm Hg should receive drug therapy regardless of risk. The treatment goal remains <130/80 mm Hg for most older adults, with higher targets allowed for frailty, orthostatic symptoms, comorbidity burden, or limited life expectancy. This approach modestly reduces medication eligibility among lower-risk older adults while maintaining intensive control for those at higher risk.
Cardiovascular risk using (PREVENT) is complicated and is best done by using the form on this link. Predicting Risk of Cardiovascular Disease Events (PREVENT. It is only valid for ages 30–79 and patients with no known cardiovascular disease. If the patient already has coronary artery disease, stroke, or heart failure, PREVENT is not applicable.
How to interpret the score
| PREVENT 10-year risk | Clinical meaning |
|---|---|
| <5% | Low risk |
| 5–7.4% | Borderline |
| ≥7.5% | Treatment threshold (new guideline) |
| ≥20% | High risk |
What was just released was not a new guideline itself, but an analysis/news report about the 2025 AHA/ACC hypertension guidelines and how they change treatment eligibility in adults 65 to 79. For patients older than 65, the key change is that age alone no longer automatically triggers drug treatment for stage 1 hypertension. Under the older 2017 approach, essentially all adults ≥65 with stage 1 hypertension were eligible for antihypertensive medication.
Under the 2025 AHA/ACC guideline, treatment is now risk-guided, using the PREVENT 10-year cardiovascular risk calculator. In practical terms, for an older adult with stage 1 hypertension (systolic blood pressure 130–139 ordiastolic blood pressure 80–89), start medication now if the patient has a 10-year CVD risk ≥7.5% by PREVENT, or established CVD, diabetes, chronic kidney disease, or other high-risk features.
If the patient is lower risk (PREVENT <7.5%), the guideline recommends lifestyle treatment first, and adding medication only if BP remains ≥130/80 after 3–6 months. The treatment goal remains <130/80 mm Hg for all adults, including older adults, with special individualization for people in institutions, with limited life expectancy, or where treatment burden/tolerance is an issue.
The new message for adults over 65 is do not treat solely because they are over 65. Do treat if BP is ≥140/90, or if stage 1 hypertension is accompanied by enough cardiovascular risk. Aim for <130/80, but individualize in frailty, institutional care, or limited life expectancy. The analysis found that, among untreated U.S. adults aged 65–79 with stage 1 hypertension, about 11.4% would no longer be started on medication under the new risk-based approach.
For a quick office summary in patients >65, blood pressure 130–139 / 80–89, high risk start meds. If low risk, modify lifestyle first for 3–6 months. If BP ≥140 / 90, start meds. The goal is <130/80, if tolerated and appropriate.
Note that the PREVENT score does not apply to patients 80 or older. Thus, these recommendations are silent as to how or if treatment for the patients should be adjusted. We have told physicians since the invention of medicine that treatment should be individualized. Recommendations like these likely come from a dark room full of physicians who treat patients like battalions rather than individuals. Doctors are best advised to consider all the aspects of their patients’ conditions before embarking on a complicated therapeutic voyage.
The paper that combines all the recommendations for treatment at all ages is appended below as a PDF. It is long and tedious. Very few readers will make it through before being overcome by somnolence. Nevertheless, it’s here for anyone who has trouble sleeping.
